All Stories

  1. Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study

    Article • Clinical Chemistry, March 2018, AACC

    Dr Eugeen Vanmechelen

  2. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease

    Article • Journal of Alzheimer s Disease, August 2016, IOS Press

    Dr Eugeen Vanmechelen

  3. Association of Plasma Aβ40 Peptides, But Not Aβ42, with Coronary Artery Disease and Diabetes Mellitus

    Article • Journal of Alzheimer s Disease, April 2016, IOS Press

    Dr Eugeen Vanmechelen

  4. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid

    Article • PLoS ONE, April 2016, PLOS

    Dr Eugeen Vanmechelen

  5. Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases

    Article • Journal of Neurochemistry, January 2016, Wiley

    Dr Eugeen Vanmechelen

  6. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature

    Article • Biomarkers in Medicine, January 2016, Future Medicine

    Dr Eugeen Vanmechelen

  7. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

    Article • Alzheimer s & Dementia, December 2015, Elsevier

    Dr Eugeen Vanmechelen

  8. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

    Article • Neurobiology of Aging, September 2015, Elsevier

    Dr Eugeen Vanmechelen

  9. A Practical Guide to Immunoassay Method Validation

    Article • Frontiers in Neurology, August 2015, Frontiers

    Dr Eugeen Vanmechelen

  10. A monoclonal antibody-based elisa for neurogranin

    Article • Alzheimer s & Dementia, July 2015, Elsevier

    Dr Eugeen Vanmechelen

  11. Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example

    Article • Alzheimer s & Dementia, July 2015, Elsevier

    Dr Eugeen Vanmechelen

  12. TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies

    Article • Acta Neuropathologica Communications, April 2015, Springer Science + Business Media

    Dr Eugeen Vanmechelen

  13. Tau Monoclonal Antibody Generation Based on Humanized Yeast Models

    Article • Journal of Biological Chemistry, December 2014, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Eugeen Vanmechelen

  14. Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels

    Article • Alzheimer s & Dementia, October 2014, Elsevier

    Dr Eugeen Vanmechelen

  15. TDP-43 AS A BIOMARKER FOR FRONTOTEMPORAL LOBE DEGENERATION: A SYSTEMATIC REVIEW OF EXISTING ANTIBODIES

    Article • Alzheimer s & Dementia, July 2014, Elsevier

    Dr Eugeen Vanmechelen

  16. Tau as a molecular biomarker in cerebrospinal fluid and plasma

    Article • Neurobiology of Aging, March 2014, Elsevier

    Dr Eugeen Vanmechelen

  17. Monitoring of β-Amyloid Dynamics after Human Traumatic Brain Injury

    Article • Journal of Neurotrauma, January 2014, Mary Ann Liebert Inc

    Dr Eugeen Vanmechelen

  18. A new era of CSF biomarker testing in the field of Alzheimer's disease

    Article • Alzheimer s & Dementia, July 2013, Elsevier

    Dr Eugeen Vanmechelen

  19. Detection and quantification of novel tau/phospho-tau epitopes in CSF using a multiplex assay approach

    Article • Alzheimer s & Dementia, July 2013, Elsevier

    Dr Eugeen Vanmechelen

  20. Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

    Article • Archives of Neurology, November 2012, American Medical Association (AMA)

    Dr Eugeen Vanmechelen

  21. Analytical aspects of molecular Alzheimer’s disease biomarkers

    Article • Biomarkers in Medicine, August 2012, Future Medicine

    Dr Eugeen Vanmechelen

  22. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

    Article • Biomarkers in Medicine, August 2012, Future Medicine

    Dr Eugeen Vanmechelen

  23. Potential sources of interference on Abeta immunoassays in biological samples

    Article • Alzheimer s Research & Therapy, January 2012, Springer Science + Business Media

    Dr Eugeen Vanmechelen

  24. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: Possible implications for tauopathies and Alzheimer's disease

    Article • Respiratory Physiology & Neurobiology, September 2011, Elsevier

    Dr Eugeen Vanmechelen

  25. Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method

    Article • Neurochemical Research, June 2011, Springer Science + Business Media

    Dr Eugeen Vanmechelen

  26. Tau protein analysis after hypothermia treatment after cardiac arrest—A pilot study

    Article • Resuscitation, December 2010, Elsevier

    Dr Eugeen Vanmechelen

  27. Added diagnostic value of CSF biomarkers in differential dementia diagnosis

    Article • Neurobiology of Aging, November 2010, Elsevier

    Dr Eugeen Vanmechelen

  28. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

    Article • Brain Research, November 2010, Elsevier

    Dr Eugeen Vanmechelen

  29. CSF tau as a diagnostic marker and therapeutic drug treatment monitor

    Article • Alzheimer s & Dementia, July 2010, Elsevier

    Dr Eugeen Vanmechelen

  30. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

    Article • Neurobiology of Aging, March 2010, Elsevier

    Dr Eugeen Vanmechelen

  31. Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

    Article • Neuroscience Letters, February 2009, Elsevier

    Dr Eugeen Vanmechelen

  32. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

    Article • Neurobiology of Aging, August 2008, Elsevier

    Dr Eugeen Vanmechelen

  33. Tau as a biomarker of neurodegenerative diseases

    Article • Biomarkers in Medicine, August 2008, Future Medicine

    Dr Eugeen Vanmechelen

  34. P3-071: Mass spectrometric characterization of tau in cerebrospinal fluid

    Article • Alzheimer s & Dementia, July 2008, Elsevier

    Dr Eugeen Vanmechelen

  35. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study

    Article • Neurobiology of Aging, June 2008, Elsevier

    Dr Eugeen Vanmechelen

  36. Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry

    Article • Journal of Proteome Research, May 2008, American Chemical Society (ACS)

    Dr Eugeen Vanmechelen

  37. Biochemistry of Tau in Alzheimer’s disease and related neurological disorders

    Article • Expert Review of Proteomics, April 2008, Taylor & Francis

    Dr Eugeen Vanmechelen

  38. P-064

    Article • Alzheimer s & Dementia, July 2007, Elsevier

    Dr Eugeen Vanmechelen

  39. P2-142

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Dr Eugeen Vanmechelen

  40. P2-146

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Dr Eugeen Vanmechelen

  41. O3-01-06

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Dr Eugeen Vanmechelen

  42. P3-090

    Article • Alzheimer s & Dementia, July 2006, Elsevier

    Dr Eugeen Vanmechelen

  43. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2006, De Gruyter

    Dr Eugeen Vanmechelen

  44. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism

    Article • Neurobiology of Disease, November 2005, Elsevier

    Dr Eugeen Vanmechelen

  45. AB42 peptides, tau, and P-tau181P as biomarkers for early diagnosis: A multiparametric approach using xMAP™ technology

    Article • Alzheimer s & Dementia, July 2005, Elsevier

    Dr Eugeen Vanmechelen

  46. Subgroups of Alzheimer disease based on cerebrospinal fluid levels of molecular markers

    Article • Alzheimer s & Dementia, July 2005, Elsevier

    Dr Eugeen Vanmechelen

  47. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers

    Article • Annals of Neurology, January 2005, Wiley

    Dr Eugeen Vanmechelen

  48. P3-049 Multiparametric biomarker quantification in cerebrospinal fluid (CSF) for early and differential diagnosis of patients with Alzheimer's disease (AD)

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr Eugeen Vanmechelen

  49. P3-031 A novel β-amyloid42 index in cerebrospinal fluid for specific determination of Alzheimer's disease

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr Eugeen Vanmechelen

  50. P4-386 The effect of simvastatin treatmnt the processing of the amyloid precursor protein in patients with Alzheimer's disease

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr Eugeen Vanmechelen

  51. S1-02-01 Amino-truncated abeta 42 species as early diagnostic and etiological biomarkers of Alzheimer's disease

    Article • Neurobiology of Aging, July 2004, Elsevier

    Dr Eugeen Vanmechelen

  52. Plasma Levels of β-Amyloid(1-40), β-Amyloid(1-42), and Total β-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins

    Article • Archives of Neurology, March 2004, American Medical Association (AMA)

    Dr Eugeen Vanmechelen

  53. Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease

    Article • Archives of General Psychiatry, January 2004, American Medical Association (AMA)

    Dr Eugeen Vanmechelen

  54. CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry

    Article • Brain Research Bulletin, August 2003, Elsevier

    Dr Eugeen Vanmechelen

  55. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

    Article • Journal of Neurochemistry, May 2003, Wiley

    Dr Eugeen Vanmechelen

  56. Cerebrospinal fluid levels of total-tau, phospho-tau and Abeta42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

    Article • Acta Neurologica Scandinavica, February 2003, Wiley

    Dr Eugeen Vanmechelen

  57. Unaltered Plasma Levels of β-Amyloid(1–40) and β-Amyloid(1–42) upon Stimulation of Human Platelets

    Article • Dementia and Geriatric Cognitive Disorders, January 2003, Karger Publishers

    Dr Eugeen Vanmechelen

  58. Association of CSF apolipoprotein E, Aβ42 and cognition in Alzheimer’s disease

    Article • Neurobiology of Aging, March 2002, Elsevier

    Dr Eugeen Vanmechelen

  59. Decreased CSF-β-Amyloid 42 in Alzheimer’s Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms

    Article • Dementia and Geriatric Cognitive Disorders, January 2002, Karger Publishers

    Dr Eugeen Vanmechelen

  60. Low cerebrospinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment

    Article • Neuroscience Letters, November 2001, Elsevier

    Dr Eugeen Vanmechelen

  61. Cerebrospinal fluid τ and β-amyloid(1-42) in dementia disorders

    Article • Mechanisms of Ageing and Development, November 2001, Elsevier

    Dr Eugeen Vanmechelen

  62. An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-α

    Article • Neurochemistry International, June 2001, Elsevier

    Dr Eugeen Vanmechelen

  63. Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice

    Article • Archives of Neurology, March 2001, American Medical Association (AMA)

    Dr Eugeen Vanmechelen

  64. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies

    Article • Neurological Sciences, February 2001, Springer Science + Business Media

    Dr Eugeen Vanmechelen

  65. CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease

    Article • Molecular Neurobiology, January 2001, Springer Science + Business Media

    Dr Eugeen Vanmechelen

  66. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

    Article • Neuroscience Letters, January 2001, Elsevier

    Dr Eugeen Vanmechelen

  67. Identification of two-dimensionally separated human cerebrospinal fluid proteins byN-terminal sequencing, matrix-assisted laser desorption/ionization — mass spectrometry, nanoliquid chromatography-electrospray ionization-time of flight-mass spectrometr...

    Article • Electrophoresis, June 2000, Wiley

    Dr Eugeen Vanmechelen

  68. Plasma Aβ42 as a diagnostic marker in sporadic Alzheimer's disease

    Article • Neurobiology of Aging, May 2000, Elsevier

    Dr Eugeen Vanmechelen

  69. CSF tau and beta amyloid may predict conversion from MCI to dementia

    Article • Neurobiology of Aging, May 2000, Elsevier

    Dr Eugeen Vanmechelen

  70. Unusual Aß amyloid deposition in Alzheimer's disease due to an APP T7141 mutation at the γ42-secretase site

    Article • Neurobiology of Aging, May 2000, Elsevier

    Dr Eugeen Vanmechelen

  71. CSF-phospho-tau as a promising marker for discriminating Alzheimer disease from Lewy body dementia

    Article • Neurobiology of Aging, May 2000, Elsevier

    Dr Eugeen Vanmechelen

  72. Subgroups of Alzheimer disease based on levels of CSF tau, ubiquitin and Aβ1−42

    Article • Neurobiology of Aging, May 2000, Elsevier

    Dr Eugeen Vanmechelen

  73. Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma

    Article • Amyloid, January 2000, Taylor & Francis

    Dr Eugeen Vanmechelen

  74. Evidence That Aβ42 Plasma Levels in Presenilin-1 Mutation Carriers Do not Allow for Prediction of Their Clinical Phenotype

    Article • Neurobiology of Disease, August 1999, Elsevier

    Dr Eugeen Vanmechelen

  75. Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease

    Article • Archives of Neurology, June 1999, American Medical Association (AMA)

    Dr Eugeen Vanmechelen

  76. The Glu318Gly Substitution in Presenilin 1 Is Not Causally Related to Alzheimer Disease

    Article • The American Journal of Human Genetics, January 1999, Elsevier

    Dr Eugeen Vanmechelen, Prof. Dr. Otto W. Witte

  77. Tau Immunoreactivity Detected in Human Plasma, But No Obvious Increase in Dementia

    Article • Dementia and Geriatric Cognitive Disorders, January 1999, Karger Publishers

    Dr Eugeen Vanmechelen

  78. Postmortem changes in the phosphorylation state of tau-protein in the rat brain

    Article • Neurobiology of Aging, November 1998, Elsevier

    Dr Eugeen Vanmechelen

  79. Tau protein in the diagnosis of old-age dementia

    Article • Archives of Gerontology and Geriatrics, January 1998, Elsevier

    Dr Eugeen Vanmechelen

  80. Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing

    Article • January 1998, Springer Science + Business Media

    Dr Eugeen Vanmechelen

  81. Microtubule-associated protein tau in human fibroblasts with the Swedish Alzheimer mutation

    Article • Neuroscience Letters, December 1996, Elsevier

    Dr Eugeen Vanmechelen

  82. Developmental expression of tau proteins in the chicken and rat brain: Rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult tau isoforms

    Article • International Journal of Developmental Neuroscience, October 1995, Elsevier

    Dr Eugeen Vanmechelen

  83. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205

    Article • Neuroscience Letters, April 1995, Elsevier

    Dr Eugeen Vanmechelen

  84. Tau protein in Alzheimer's disease

    Article • Biochemical Society Transactions, February 1995, Portland Press Ltd.

    Dr Eugeen Vanmechelen

  85. Generation and characterization of mouse microglial cell lines

    Article • Journal of Neuroimmunology, July 1994, Elsevier

    Dr Eugeen Vanmechelen

  86. Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-Linked Immunosorbent Assay

    Article • Journal of Neurochemistry, November 1993, Wiley

    Dr Eugeen Vanmechelen

  87. Specific Neisseria gonorrhoeae DNA-Probes Derived from Ribosomal RNA

    Article • Microbiology, June 1989, Society for General Microbiology

    Dr Eugeen Vanmechelen

  88. CSF Markers for Early Alzheimer's Disease

    Article • Wiley

    Dr Eugeen Vanmechelen